- Rite Aid takes a bite out of obesity; relaunches weight-loss program for New Year
- A look at China's retail pharmacies
- Retail pharmacy emerging as healthcare necessity
- Loose ends should be tied to make e-prescribing a reality
- DEA allows controlled drug e-prescribing, handing pharmacy advocates a key victory
NEW YORK — A new bill in Florida's state legislature would allow pharmacists to substitute biosimilars for branded biotech drugs, according to published reports.
The Sarasota Herald-Tribune reported that the Health Quality Subcommittee of the Florida House of Representatives approved a bill that would allow for substitution while requiring pharmacists to notify prescribing physicians within five days and require the doctor and pharmacist to maintain a record for at least four years.
The Patient Protection and Affordable Care Act included a regulatory approval pathway for biosimilars, though the Food and Drug Administration has yet to finalize regulations for them.